%PDF-1.7 % 6 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20190918065452+02'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 7 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 5 0 R ] /PZ 1 >> endobj 7 0 obj <> stream xZMRHH%U# %$C!b*dіڢSRҒLc@Αs1f\`vV CR2,ے}??\ pC wK齟YHa܍S }`tNoBۉl~ qNOƻ[zuտ` {򒃾繮9>\M ogٕ?Z^-h0 hۇDB\΋:a?@Aֹ&^חTX+Q *%mfX*dSUESasucU6&DLXu'qh-CPx~ĂOGMA,YmXRWfJjI2fqD.ЂӺ2%mT)-]o?YCE7Aᢃn*grdh! -P +Ǵu++i53yzT2V"SGGlcZfׁv0>ϐ6uZe])L}jhnh7kIbmRgn=gy@,AS Ig*´A УԢ $ԒA+T4h3ζb"4?\}T\,7+˓G}:u"脻E٦Jj5)U L4MΪ!0+sGb:xw/&+ F)xѧe;`IS`W. Bh%rq^fQr}XxXPAFj@VAh׷Vn%ϯ H'SN)+g\$EDMH$dS x.tpĭƨAzbmj4E )Q|  R.6dYhh @E W>8à'1CK@BcSIPeP$Jy4"e+Od&Sl̩xuksy\"⡟ nr\ZGA% J ]8i/tLW0(V4I\ChD%Lk`)ч?OA,؇~>0O2ڞ+&6"3.GjX1rBM&$h0G'-Tn(=㺏ϔ!_`肥ô"@G3,IK7,Dr>>}`Ձ1  l:13 gKPFgnJsڙ.Yĝ&p+eZ%D@ჼ\RU*i O9@ms"Vf5DYJʒ'TY1(^9uT3C/7kh+nǹ5B.-N15sǑZCv2ѼRM.bVlqO[_ "1(?2Oh8 sA91-<yhJ2|:.t<|' Wi#b˘xJ.wVXˍ0Ε ܷ~IFd1OKφH}ldVQ+{lqJ*1:5g r@K@VxhRܨHi.T:pK>mSionN7jnp¥CꏖD؏".®9DHhvן~ɴolkܾO 8F endstream endobj 1 0 obj << /Type /Pages /Kids [ 6 0 R ] /Count 1 >> endobj 3 0 obj <> endobj 4 0 obj <> endobj 8 0 obj <> /Resources <> /Font <> /ExtGState <> /ProcSet [/PDF /Text /ImageB /ImageC /ImageI ] >> /Filter /FlateDecode /Length 848 >> stream xWmO0^c$H (똆AIC|J(ՠemIªل׹Gdw7>9<GkDžaW$<"H2|R(29:9$^-e>..y.Gd:|VCd` ')ɮB(TEҒ %% E֙ J,$BDO&D>MH0-6=C.h&CfR\ X+b :Nic*k+ p.}&xs|"8 n,v )W-6o=߸hNftK:M[ۀr!e\KeAky$RP<⺍pxup8>H  M{qI3_w,縲eGfNՑmna.hȓjYU,b\2OuyZ6#sC͚3gkriӲ ly#4]kDfu |w*lm O镸080iIsӵһ%7/i\XJ.̚5K5jM9aq'wqh%Q*i gyQ(p]5'CԫkSuRCln_*9{.+|FAqp-Pg*O hsRՎSJ&`1U$GBHB-K5NюG~?Rh#%SkC3a-r"7αը $O+ o endstream endobj 14 0 obj <> endobj 13 0 obj <> endobj 16 0 obj [250 0 0 0 0 0 0 0 0 0 0 564 0 333 250 0 500 500 500 500 500 0 500 500 500 500 0 0 0 0 0 0 921 0 0 0 722 611 556 722 722 0 0 0 0 889 0 0 556 0 667 556 0 0 0 0 0 0 611 0 0 0 0 0 0 444 500 444 500 444 0 0 500 278 0 500 278 778 500 500 500 0 333 389 278 500 500 722 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 ] endobj 15 0 obj <> endobj 12 0 obj <> stream x  Om7^ Oa endstream endobj 17 0 obj <> stream x nH@o endstream endobj 11 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( m{HV*ڝ 2֍sD$;k]-j** jmZކ6PϷXkW״y,H$c``qW_Wx4pYd]pI"TnϿD1Vn57N]KEgi70n63# :*Zޡyڬ4:Гp vFJ{m龖u_!Fxgnz犯6cjP <,08 - bE^Z7wmfON4%pJ<H%f\OnMowC۾ǽG6<_jx0&s7kvߙokVkY~nn䲺k[X0eXuV ~ILA+G#I(D8qc=>J'}77h/Uknmkkb 0yHw/6@2nY*pMzU3%ėڌʻe/9I>OS_zwqlTM$1!vzڥʺy22eg{/㱷EgX\?lJ8cU4I #|K3G|T{ƿZZunTpCp*H1S0I\։r,f ěsR>hJq:Z+ -kP[ '̀ 8B޻F9fB<8D>hݴ5NDn+E說uZk6(95Gyd , 9kVh驖cdex[O!U'}me}SZwТ5;hMΌR ϲp"5iOW|LS d {u*mMow4Z4baIXcnf>L«hIc}h4lHg'R*uٽ~ocVʳէ{~`HdS!r+3Cm{TWx24VgQccm{u"=ŰNy'&U Eٻ~-lNr֨WIѥ;W>z+YT3*RWi4׫8ȗĚ̐Zrо ~EO XOԒM]mllͭ[#l%IMIikV"v''EPG9@``n^s _vbWe[3ImjK}\iY >}Ac1GI]VkזׂMKsn!rK2@ێ=xku{MJ8EDR.v)_KIkz>M +mv_k2sRj#$d>Zl;5i!)70 :^v?Rnm{ZnkYWzXiqVj a idzI cK>n[}鹭Eb6q6wXy۰Mqjk Vy4Qotdtf߯QRSmZmB;iI $l3gVf]&k|QlaB$&pL#oN55&!b+rVvپz]ڽivI:@$Yv&F'>m͵ 3D[pe=OqIњWȨi\iQX"v:k"H)2Hb9$rN3[3(;HUY^љ] ʇ O|k%ՐVfrkzxшLn\]:Jq|JǶkRwooYRm,ѵӱYWz\bIYؑ'}(n^EEDzM"5u}f7/vkX$*8!YbEi" H򤌌3\'m9CqqJֲ: @KgɜL*A}gK$խS/+mEaEjw -ӬfY< ~5$!?ɫG 0xXemH=y*^KFW+]WA Xrڨktk@¼eeی;g5O]M絷ZD2m1|prQ}]DTӌ%%{{Ym(eB$18 d>i:v N2FGҥQ_r劥z/=4\ې&8Nx8Ts~V=Z X'g"YVwqw6q#$ӄ#%0U8KHi$7WSЩȧU ZhQRYv~RiS ((((m6d պᅾ[UM#zͽЬon>$78ǝ6#܎k G^5ZsUZzYjrik$XrIj[)R?}馕mm43|\ ێgH{ JqӗFk[]-4Iq)J,iAD['ciHF:VZ<Li>sBz'}֤pK{ ۩3B<EŜR*>H?J̩ay'rXP 's29cM.+j)CE*B VgY\fY.z e(FjW%# tΜYZs>߱IgԵkm."ٖ7qy$lgzun>%u?JjI&:LԖ:=: $qi =ңBm N[Wߦ~E=t>?Q7H,ඞh.4$䁏CYzT6O'$cuW3~V,ZSQ+͓&#.mjDL$hqQ (I_ZnSGMHᷓE2X\m3 vWF4 0[c,=֧mt- Yy5B TaIۖ6׽yEU Zb}?nTvpXbR]I䜚59.NJ0{rvZ5Oyu wmm<=XγfUıLoeDIp9'$ ~bvh`^Q\n3j:Ykd$h"0x侖ad̛Fߘ`Zzٻ<v,=:E: !a,,]ds9j4Vvc,=iJ[J[e_M\vAjϚ9%>- KwJܗGQ[JnLr2@ 7\ӊ^).P{sIavzƕi-vtأO k-od@_rpGo?Kb{#vDbz?[}&M37 i<$t9׭ZAIK=TZוOVe;l?ʹ^?*J`EKifXҪkOՉʭ2_7o+a})!7&t2U=>-[E5w<7QGcVz=iX:i t'ҫ/rY.+ 1ӌө7oLε |$m[׺h&$wX6+ $tVN{w 5HaҭW;嶇ly (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( endstream endobj 10 0 obj <> stream x  Om783  endstream endobj 18 0 obj <> stream x nH@paX endstream endobj 9 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222bb" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( *kZ= )՘W5mZx?sS)(rbzz.-+E_|dF>g?qZP ]3N'K:?ƸT/.\$s1c 'j9W᭏=Mrķsݓ@aGrZ}{R}NՋHf?^d!,.@#VnZ)BJPG i6ב9O?0H\kǝףG1>X;} ExM_@eZ}H2Bo_U a1Jr˺-aUL cZݫ L7YSG/k?oo\jSѫV]֙宙>bx.2)YWN/XޑxVRr{W\֡p~Z7gS憌#ˌ5JOkT{Y$9$5b'JAI a}%hT(((kH0zVBEY[RI(GJ?zӉ[?kFniE?D;o l_DP^Xž "Lh?g |{עW|mIW̗ɏL,WQCz-Wv\@He@єRWWTV.⤂( ( ( ( ( ( ( ( ( ( ( ( ( ziSs('*:e>#j\!eG9_Ɍ-/S#N_GxA'4?2+><(niv%Lp?aG2_Iѽ~kNe>XՂ (((((F`Y I=c9ũՍ0}E $=M ||?hjz#59½OC+oEQEQEQEQEQEQEQEQEQEQEQEQEW;65(jnm;<>/sW~ʯT4bXZJy UEYk (;QEIaEPEPYֳmX5,x0yvmwĶZDH[>X>Uծ{ƹ|EQPz^*ϚzG<\7.7y^V/ԯe}Hr}~SZs;p } J*:ӟ4lNHcfF q*<%s] o,z'eд ( ( ( ( ( ( ( ( ( ( ( ( ( +h[TělOSa )CV &8ş#im ҺkIT׆>+)lݶ~^ s_QJT~΢7ȩk>l]GȮϟekYx^=+Spߊ\5l5*F\u|+)[˧{%{|=?Z5o^݆1i~r?5Q]r4ڻUfԜ?t=*ߔ<3cVoĒkN_Wr>ʍ?g+P(((((((((((((߄a~*^Ù-e?އ?_5/e(H+ωOMUM^%t ;{cb3 cuV`k8 s\j=KtquV s^d|':d4sYP:մg:M訄y+E3Q@rLPw܁ޕ#Iifu˫梹k j%#a[a{vX5 <]/.Ѱ(vO},: q̧0cw>g`p IQ^QQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@g..-55\%ʯwG^ Yٵ;V's[ӭ}]U-5;Gr`:'KG9k!W]򥾣Z1_k|CJ}9[ϗo?לj^n4學W/#{l[%вEK]Ha*AsΖQ^ZNƿsҎq,: oY杦sZ/~u2IO~?.e_XsX?k*?2G}%pƹ&=K!..;QGonZ/ i4(|<կ'Ov/`OW (((((((((((((((<2"V`)\>|v08 Z( ( ( +7YcSFڇc65Mťvnɕ/4;P+_Nc,b=MNQى/ts)QПkRú.A,`aѣE?MD : nލPcϢ5-AAEPExK֧O`-a9?iKa9$osN(0(((((((((((z+qBԃTs\q [3kG|?wwXEu2դB)Mj὜6R~j6dTFLr@ bWW9]،EJxYۡÇNxxt8+z$oR>V>VNj|=i1}j$|$|t7WDx%y"E:9/ \ PI4A({U~ Z;u՛!/+s%K1 @A#k>X;CUB]TU88s-wrpq~j ;ƻnŧ H\4`N΀XzYTs)ՔtI)bH5K ,RFQ2l{&o~,fl;|Aj~)XeزE PsʁV<mw[iOl#dP ޠnNsZBp7i}pI$Js6qnD1ykZ<:ڹcԓ'T&*mNYQT18J^)jkoEe [xZfm,Y@Ԍ m:/Ŧ<.مP;zV?~6ݶy ޹U9B&TeOI껛V 4jTFN `Ӯr+GP%_VFBI( Z|%]Z-C;bn8 GB+v-A𦩨뗷r2z8JrSV۶2ԋ$~д}14Ni^#K! D, O@NzWH%Kkw* B2O%{w?ABӯ{i Ȇ(@3d凄\ݕLqz>-6y jp>?|aP>?9j? C|XehmQ (8C\F|µ 'kt♜k OkhS bSyp0Y[\!<yj3EqO $R(du9 Ba"։.co2g夑8?s׍ëw17Ṿ; Q\:}$_;{=SOGXUp\*%7?g۰sy9yF hYj ۙrT𮓩hRi_b8cpiZ\U4JmEp_ u+ Kor'8LI1]aV7ڕER kQEQEQEQEQEQEQEQEQEUMVO+G?)V覝Տ#m  hVZTo ?ٮX>94 iW1bOy'yEt Tu9u 6un/ ?FrDeQ`~xk^ \v-kG"NZퟝLWQJ8:nאU쒷y^d)Ze1ijd`u?zYC/&wnF1ֽrj5ǚM᫏"lB֪$9YK=2 *ޑ"lb4J-V%)lXÌ޽Onkӄgc$KymhfkuRn3[KjIoXԱ?^WUE%^ܖ_ N%c˼]!-ge2X0EzMImnCDd{ EMJQV—$/U) %qm"HAg{_ĈUڊJ 5%r6]5a)4$UM9 ៥kMxWubh0?,~:~5TVZӎ3ZK[_|AYk%ڬA OL~|5YP1cBgz 3s)+n ?+'ʟٞmc ,\ӱ3@{ d+ːJёé=qz:)iE-WQf y`JE;!4c ~c[L?= $v$7>#^&Yk%X,O$U > /XObject <> >> endobj 5 0 obj <> /H /I>> endobj 19 0 obj << /Title (DAIICHI SANKYO premiata per il "Miglior portafoglio prodotti di farmaci cardiovascolari") /Author (Daiichi Sankyo) /Subject (DAIICHI SANKYO premiata per il "Miglior portafoglio prodotti di farmaci cardiovascolari") /Creator (TCPDF) /Producer (TCPDF 6.2.26 \(http://www.tcpdf.org\)) /CreationDate (D:20190918065452+02'00') /ModDate (D:20190918065452+02'00') /Trapped /False >> endobj 20 0 obj << /Type /Metadata /Subtype /XML /Length 4419 >> stream application/pdf DAIICHI SANKYO premiata per il "Miglior portafoglio prodotti di farmaci cardiovascolari" Daiichi Sankyo DAIICHI SANKYO premiata per il "Miglior portafoglio prodotti di farmaci cardiovascolari" 2019-09-18T06:54:52+02:00 TCPDF 2019-09-18T06:54:52+02:00 2019-09-18T06:54:52+02:00 TCPDF 6.2.26 (http://www.tcpdf.org) uuid:d565eaf2-228d-e3f9-1cb5-d1eed9bcd9c2 uuid:d565eaf2-228d-e3f9-1cb5-d1eed9bcd9c2 http://ns.adobe.com/pdf/1.3/ pdf Adobe PDF Schema http://ns.adobe.com/xap/1.0/mm/ xmpMM XMP Media Management Schema internal UUID based identifier for specific incarnation of a document InstanceID URI http://www.aiim.org/pdfa/ns/id/ pdfaid PDF/A ID Schema internal Part of PDF/A standard part Integer internal Amendment of PDF/A standard amd Text internal Conformance level of PDF/A standard conformance Text endstream endobj 21 0 obj << /Type /Catalog /Version /1.7 /Pages 1 0 R /Names << >> /ViewerPreferences << /Direction /L2R >> /PageLayout /SinglePage /PageMode /UseNone /OpenAction [6 0 R /FitH null] /Metadata 20 0 R >> endobj xref 0 22 0000000000 65535 f 0000002303 00000 n 0000022228 00000 n 0000002362 00000 n 0000002468 00000 n 0000022354 00000 n 0000000015 00000 n 0000000483 00000 n 0000002579 00000 n 0000013729 00000 n 0000012936 00000 n 0000005266 00000 n 0000004706 00000 n 0000003853 00000 n 0000003797 00000 n 0000004454 00000 n 0000004039 00000 n 0000005013 00000 n 0000013417 00000 n 0000022570 00000 n 0000023213 00000 n 0000027715 00000 n trailer << /Size 22 /Root 21 0 R /Info 19 0 R /ID [ ] >> startxref 27924 %%EOF

DAIICHI SANKYO premiata per il "Miglior portafoglio prodotti di farmaci cardiovascolari"

Il riconoscimento viene dalla rivista americana R&D Directions Magazine

Roma/Monaco, 11 marzo 2009 - La rivista internazionale R&D Directions Magazine, specializzata nel settore farmaceutico, ha riconosciuto a DAIICHI SANKYO la Migliore Pipeline di prodotti cardiovascolari in Ricerca e Sviluppo per il 2009, grazie soprattutto a due promettenti farmaci, EFIENT® e Edoxaban (DU 176b). L’azienda “ha raggiunto significativi risultati nella lotta contro le malattie cardiovascolari”, afferma il giornale. Oggi DAIICHI SANKYO riceverà ufficialmente il premio durante la cerimonia di premiazione R&D Directions a Phoenix in Arizona.

“È un premio ai nostri ingenti investimenti in Ricerca&Sviluppo finalizzati ad offrire a medici e pazienti trattamenti innovativi per le malattie cardiovascolari, che in Italia causano complessivamente oltre 240mila decessi ogni anno”, così Antonino Reale, presidente e amministratore delegato di DAIICHI SANKYO ITALIA, ha commentato il riconoscimento internazionale.

Secondo la rivista americana DAIICHI SANKYO possiede il miglior portafoglio prodotti cardiovascolari in Ricerca&Sviluppo fra le aziende farmaceutiche con particolare riguardo a EFIENT®, farmaco antiaggregante e a Edoxaban, anticoagulante, quest’ultima molecola di grande potenziale in fase di sviluppo. DAIICHI SANKYO è una delle tre aziende al mondo che conduce ricerche in entrambe le aree degli anti-coagulanti e degli antitrombotici, dove è attiva da più di 25 anni.

R&D Directions Magazine ha sottolineato inoltre che l’azienda giapponese si è contraddistinta negli anni per una serie di considerevoli scoperte, dalla classe delle statine al successo dell’antipertensivo OLMETEC®.

“Crediamo di fornire un contributo significativo ad un’area chiave della medicina e siamo fieri che i nostri sforzi e i nostri farmaci abbiano ricevuto questo riconoscimento” ha dichiarato John Alexander, a capo della divisione Ricerca&Sviluppo DAIICHI SANKYO. “Nell’Unione Europea le malattie cardiache coronariche rappresentano la principale causa di morte, con oltre 741.000 decessi all’anno. Noi crediamo che i medici e i loro pazienti abbiano bisogno di nuove terapie per trattare queste patologie, e il nostro portafoglio prodotti soddisfa queste esigenze”.